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Comments regarding ‘Venous Angioplasty is Safe to Perform and May Have
Beneﬁts Forin Patients with Multiple Sclerosis. Results of a Pilotcase Control Pilot
Study’
J. Beard*
Shefﬁeld Vascular Institute, Herries Road, Shefﬁeld S5 7AU, UKThis small pilot study follows on from the prospective study of
65 patients by the same group, published in the Journal of Vascular
Surgery (JVS) in 2009.1 The authors do not explain what this small
pilot was supposed to achieve in terms of a power calculation for
a larger trial, nor do they explain the rationale for the strange
methodology of submitting half the group to immediate treatment
and the other half to delayed treatment at 6 months. Presumably,
they felt that patients would not agree to enter the trial unless they
received treatment? This is not the usual basis for planning
a randomised controlled trial and one that is unlikely to be
acceptable to any organisation that might fund a larger trial in the
future. If the authors are serious about their conclusion that a large
multicentre randomised trial is now required, then this pilot should
have been designed with more attention towards the design of that
trial.
The authors suggest that one of the objectives of this trial of only
15 patients was to assess safety. The number was wholly inade-
quate to answer this objective, especially in view of their previous
larger study and another much larger study of 564 endovascular
procedures in 331 patients from Poland.2 Whether or not the
procedure is safe, and many think that it is not, other questions
remain, including the possible pathophysiological mechanisms of
chronic cerebrospinal venous insufﬁciency (CCSVI). The authors
and others claim that CCSVI is a syndrome characterized by stenosis
of the internal jugular and/or azygous veins and formation of
collateral venous channels. They claim that these stenoses are far
more common in Multiple Sclerosis (MS) sufferers but other
researchers have found no increase in the frequency of these
abnormalities in MS sufferers compared to normals.3
The last and possible the most important question is whether
the procedure is efﬁcacious both technically and clinically. The
authors own results are disappointing in respect of the technical
question, as their one-year patency rate was only 73%. Restenosis* Tel.: þ44 114 2715534; fax: þ44 114 2714747.
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nised and suggests that, even if the treatment was shown to be
clinically efﬁcacious, many patients would need regular treatment.
The question of clinical efﬁcacy will be the most difﬁcult to answer.
Studies of treatment for MS are notoriously difﬁcult to undertake
because of a large placebo effect. Measurements of function/
disability can be inﬂuenced in this way unless the treatment is
blinded. That seems impossible as it would require patients to be
randomised to endovascular treatment or a sham procedure, which
would be ethically unsound. Therefore, for any future trial, an
objective measure such as MRI lesion volumes, assessed by a radi-
ologist blinded to the treatment given will be required.
There is great excitement in the MS community about the
potential beneﬁts of endovascular treatment of CCSVI. A search of
Google reveals over 1million results andmany of these are fromMS
sufferers and their organisations asking why this treatment is not
being funded. The answer is that a publically funded healthcare
organisation should not fund any treatment that has not been
shown to be safe, efﬁcacious and cost-effective. The authors have
contributed evidence which they believe advances the cause of
CCSVI, but they missed a great opportunity to inform the design of
a large multicentre randomised trial.References
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